We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+45.78%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$159M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow
% of AUM
86.65%
Top 10 Holdings %
Top 10 Hldgs %
52.06%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$13.7M |
| 2 |
HCA Healthcare
HCA
|
+$8.42M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$8.1M |
| 4 |
AbbVie
ABBV
|
+$7.8M |
| 5 |
Zimmer Biomet
ZBH
|
+$7.75M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Baxter International
BAX
$13.5B
| $13.8M | 8.69% |
+165,000
| New | +$13.7M |
|
|
2
HCA Healthcare
HCA
$90.5B
| $9.27M | 5.84% |
+62,700
| New | +$8.42M |
|
|
3
Vertex Pharmaceuticals
VRTX
$137B
| $8.76M | 5.52% |
+40,000
| New | +$8.1M |
|
|
4
AbbVie
ABBV
$451B
| $8.32M | 5.24% |
+94,000
| New | +$7.8M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.25M | 5.2% |
+64,000
| New | +$6.17M |
|
|
6
Zimmer Biomet
ZBH
$19.2B
| $8.16M | 5.14% |
+56,135
| New | +$7.75M |
|
|
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
| $7.78M | 4.9% |
+130,400
| New | +$5.86M |
|
8
Edwards Lifesciences
EW
$52B
| $6.3M | 3.97% |
+81,000
| New | +$6.32M |
|
9
Cigna
CI
$73.7B
| $6.13M | 3.87% |
+30,000
| New | +$5.5M |
|
10
Ascendis Pharma A/S
ASND
$16.3B
| $5.86M | 3.69% |
+42,100
| New | +$4.68M |
|
|
AXNX
11
DELISTED
Axonics, Inc. Common Stock
AXNX
| $5.76M | 3.63% |
+208,000
| New | +$4.96M |
|
|
HZNP
12
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.43M | 3.42% |
+150,000
| New | +$4.6M |
|
13
NextCure
NXTC
$27.9M
| $5.24M | 3.3% |
+7,750
| New | +$3.89M |
|
|
CTLT
14
DELISTED
CATALENT, INC.
CTLT
| $5.18M | 3.26% |
+92,000
| New | +$4.69M |
|
15
Aurinia Pharmaceuticals
AUPH
$2.17B
| $4.7M | 2.96% |
+232,000
| New | +$2.14M |
|
|
DVAX
16
DELISTED
Dynavax Technologies
DVAX
| $4.46M | 2.81% |
+780,000
| New | +$4.17M |
|
17
Abeona Therapeutics
ABEO
$339M
| $4.33M | 2.73% |
+53,000
| New | +$3.74M |
|
18
DexCom
DXCM
$34.3B
| $4.16M | 2.62% |
+76,000
| New | +$3.6M |
|
|
MNTA
19
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $3.95M | 2.49% |
+200,000
| New | +$3.2M |
|
20
uniQure
QURE
$3.38B
| $3.94M | 2.48% |
+55,000
| New | +$3.02M |
|
21
Coherus Oncology
CHRS
$218M
| $3.86M | 2.43% |
+214,500
| New | +$3.96M |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $3.76M | 2.37% |
+830,000
| New | +$3.04M |
|
23
Collegium Pharmaceutical
COLL
$786M
| $3.7M | 2.33% |
+180,000
| New | +$3M |
|
24
Neurocrine Biosciences
NBIX
$15.7B
| $3.55M | 2.24% |
+33,000
| New | +$3.46M |
|
|
IMMU
25
DELISTED
Immunomedics Inc
IMMU
| $2.96M | 1.87% |
+140,000
| New | +$2.47M |
|
Similar funds
DCM
SIG
PFA
ANB
CWM
RIP
TAM
B
Avidity Partners Management's Q4 2019 Portfolio in Review
Q4 2019 is the first quarter with a 13F filing on record for Avidity Partners Management, which disclosed 33 positions worth $159M. Its ten largest holdings account for 52% of the portfolio.
Its largest position is Baxter International: 165,000 shares worth $13.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Avidity Partners Management's largest Q4 2019 buy was Baxter International: 165,000 shares worth $13.8M.
- Avidity Partners Management's ten largest holdings make up 52% of its $159M portfolio in Q4 2019.
- Avidity Partners Management disclosed 33 positions in Q4 2019, its first 13F filing on record.
Based on Avidity Partners Management's 13F filing for Q4 2019, filed 14 Feb 2020.